SCREENCELL

Company Snapshot

Founded: 2010
Entity Type: Private
Region: France
Segment: Cancer Detection
Headquarter: Paris, France
Key Geographics: Europe
Corporate Address: 62, rue de Wattignies, Paris 75012 France Tel. +33-0-18232-3130 www.screencell.com

Company Overview

ScreenCell uses size exclusion technology to separate CTCs from blood samples. ScreenCell’s products separate CTCs based on size, with the CTCs being larger compared with the nucleated bloods cells. The devices use a microporous membrane filter with defined pore sizes.

ScreenCell markets three different formats for its ScreenCell kits: Cyto (for cell enumeration and cytology), CC (for culturing of CTCs) and MB (for molecular analysis).

SCREENCELL In Reports

Next-generation Sequencing: Emerging Clinical Applications and Global Markets

Discover BCC Research's report on Next-generation Sequencing Market is steadily being integrated into clinical laboratory analysis, testing, and disease diagnostics in healthcare sectors globally.

Circulating Tumor Cell (CTC) Diagnostics: Technologies and Global Markets

BCC Research Market Report for Circulating Tumor Cell (CTC) Diagnostics. Global CTC Diagnostics Technologies market trends, with CAGRs through 2026.

Next-generation Sequencing: Emerging Clinical Applications and Global Markets

BCC Research Market Report says clinical next-generation sequencing (NGS) should grow from $5.9 billion in 2020 to $22.9 billion by 2025 with a (CAGR) of 31.4%.

Company's Business Segments

  • Cancer Detection : Isolation kits for circulating tumor cells for Cytology, Molecular biology, Cell culture.

Applications/End User Industries

  • Oncologists
  • Healthcare
  • Clinics
  • Isolation Kits
  • Circulating Tumor Cells
  • Cancer Cells
  • Molecular Biology
  • Cytology
  • Morphology
  • ScreenCell Technology
AI Sentiment